Randomized Phase II Trial of Endocrine Therapy With or Without Ribociclib After Progression on Cyclin-Dependent Kinase 4/6 Inhibition in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer: MAINTAIN Trial
Would you keep treating with CDK4/6 inhibitors and just switch endocrine therapy after failing first line ET+CDK4/6 inhibitor? This trial says YES….